CADTH Canadian Drug Expert Committee final recommendation: Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.) Indication: pulmonary arterial hypertension
The CADTH Canadian Drug Expert Committee (CDEC) recommends that selexipag be reimbursed for long-term treatment of idiopathic pulmonary arterial hypertension (PAH), heritable HPAH, PAH associated with connective tissue disorders, and PAH associated with congenital heart disease, in adult patients wi...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, October 26, 2016
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that selexipag be reimbursed for long-term treatment of idiopathic pulmonary arterial hypertension (PAH), heritable HPAH, PAH associated with connective tissue disorders, and PAH associated with congenital heart disease, in adult patients with World Health Organization (WHO) functional class (FC) II to III to delay disease progression |
|---|---|
| Physical Description: | 1 PDF file (6 pages) |